Exploratory Study is First to Evaluate Novel microRNA Replacement Therapy for the Treatment of Malignant Pleural Mesothelioma First Clinical Trial Evaluating EDV” Nanocells Packaged with microRNAs /PRNewswire/ — EnGeneIC, Ltd. , an emerging biopharmaceutical company focused on developing its proprietary EDV nanocell platform for the targeted delivery of cancer therapeutics and other therapeutic molecules, announced today that, together with the Asbestos Disease Research Institute , it has initiated the first clinical trial evaluating its bacterially-derived and antibody-guided EDV nanocells packaged with microRNA for the treatment of patients with malignant pleural mesothelioma .
